SynthesisBMC pulmonary medicine2026
Global landscape for pulmonary fibrosis treatment: a data-driven perspective from clinical trials.
Synthesis in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo systematically map the global landscape, evolution and key characteristics of interventional clinical trials in pulmonary fibrosis, providing an empirical basis for future trial strategies and resource allocation.
methodsThe INFORMA Pharma Intelligence database was searched to identify 1,203 interventional PF trials. Descriptive statistics were applied to analyse temporal trends, geographic distribution, sponsors, trial phase and status, primary endpoints, drug targets or mechanisms, and the disease spectrum.
resultsGlobal pulmonary fibrosis trial activity displayed a three-stage growth pattern, with a surge in 2020. Research is highly concentrated geographically: the United States (316 trials) and China (285 trials) dominate, yet only 128 trials are multinational. The pipeline remains centred on nintedanib (94 trials) and pirfenidone (88 trials), while target diversity is expanding, especially toward anti-angiogenic and multi-tyrosine-kinase inhibitors. Primary endpoints focus on safety or tolerability and Forced Vital Capacity change. The disease spectrum has broadened from idiopathic pulmonary fibrosis to include Connective tissue disease-associated fibrosis.
conclusionsPulmonary fibrosis clinical research is experiencing unprecedented dynamism and diversification, transitioning from targeted therapy towards precision and multimodal intervention. Enhanced international collaboration, optimized trial design, and deeper precision-based stratification will be critical to advancing the field from slowing disease progression to reversing tissue damage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.